Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder
A legfontosabb adatok
- Ki végzi
- New York State Psychiatric Institute
- Hol
- New York (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 1/2. fázis
- Kezdés
- 2022. márc. 1.
- Befejezés
- 2024. máj. 8.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Nabilone
- Placebo
- A regiszteradat frissítve
- 2024. május 21.
- Miért állt le
- The Principal Investigator is no longer at the Institution and a request for early termination of the grant supporting the study was submitted to NIH.
Ki vehet részt
- Életkor
- 21 év – 55 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Between 21-55 years of age
- Physically healthy and, if female, not pregnant
- Able to tolerate all study procedures
- Able to provide written informed consent to participate
- Right-handed
- Primary diagnosis of OCD
- Not taking psychotropic medications or other substances likely to interact with nabilone
Ki nem vehet részt
- History of receiving cognitive behavior or exposure-based psychotherapy in the past 3 months
- History of any significant medical condition that may increase the risk of participation
- Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation (e.g. lifetime psychosis or bipolar disorder)
- Current substance use disorder
- Any history of adverse reaction to a cannabinoid
- History of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)
- History of claustrophobia or unable to tolerate confined spaces like an MRI
- Females who are pregnant or nursing
- Positive urine toxicology or alcohol breathalyzer
Helyszínek itt: Egyesült Államok
- New York State Psychiatric InstituteNew York, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this research study is to test how a medication called nabilone (Cesamet) affects neurocognitive processes involved in obsessive-compulsive disorder (OCD), including threat response, processing of fear signals, and habitual behavior. OCD is a disabling illness that affects around 2% of the population and involves recurrent intrusive thoughts (obsessions) and repetitive behaviors (compulsions) that lead to distress and/or impaired functioning. Nabilone is a synthetic form of delta-9-tetrahydrocannabinol (THC, the primary psychoactive component of the cannabis plant). It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD symptoms. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.
A teljes eredeti leírásKevesebb
In this study, 60 adults with OCD will receive a single dose of either nabilone or placebo. Participants will then complete a series of assessments including neuroimaging, psychophysiology (e.g., skin conductance recording), computerized behavioral tasks, and self-report measures. The information gained from this study could contribute to the development of new treatments for people with OCD and related disorders.
A vizsgálat 2 csoportja
- NabiloneMár használt kezelés, összehasonlításként
In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
- PlaceboPlacebo, összehasonlításként
In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2024. május 21.